Literature DB >> 30333171

αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26.

Davor Nestić1, Taco G Uil2, Jiangtao Ma3, Soumitra Roy2, Jort Vellinga2, Andrew H Baker4, Jerome Custers5, Dragomira Majhen6,2.   

Abstract

Human adenoviruses (HAdVs) are being explored as vectors for gene transfer and vaccination. Human adenovirus type 26 (HAdV26), which belongs to the largest subgroup of adenoviruses, species D, has a short fiber and a so-far-unknown natural tropism. Due to its low seroprevalence, HAdV26 has been considered a promising vector for the development of vaccines. Despite the fact that the in vivo safety and immunogenicity of HAdV26 have been extensively studied, the basic biology of the virus with regard to receptor use, cell attachment, internalization, and intracellular trafficking is poorly understood. In this work, we investigated the roles of the coxsackievirus and adenovirus receptor (CAR), CD46, and αv integrins in HAdV26 infection of human epithelial cell lines. By performing different gain- and loss-of-function studies, we found that αvβ3 integrin is required for efficient infection of epithelial cells by HAdV26, while CAR and CD46 did not increase the transduction efficiency of HAdV26. By studying intracellular trafficking of fluorescently labeled HAdV26 in A549 cells and A549-derived cell clones with stably increased expression of αvβ3 integrin, we observed that HAdV26 colocalizes with αvβ3 integrin and that increased αvβ3 integrin enhances internalization of HAdV26. Thus, we conclude that HAdV26 uses αvβ3 integrin as a receptor for infecting epithelial cells. These results give us new insight into the HAdV26 infection pathway and will be helpful in further defining HAdV-based vector manufacturing and vaccination strategies.IMPORTANCE Adenovirus-based vectors are used today for gene transfer and vaccination. HAdV26 has emerged as a promising candidate vector for development of vaccines due to its relatively low seroprevalence and its ability to induce potent immune responses against inserted transgenes. However, data regarding the basic biology of the virus, like receptor usage or intracellular trafficking, are limited. In this work, we found that efficient infection of human epithelial cell lines by HAdV26 requires the expression of the αvβ3 integrin. By studying intracellular trafficking of fluorescently labeled HAdV26 in a cell clone with stably increased expression of αvβ3 integrin, we observed that HAdV26 colocalizes with αvβ3 integrin and confirmed that αvβ3 integrin expression facilitates efficient HAdV26 internalization. These results will allow further improvement of HAdV26-based vectors for gene transfer and vaccination.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  adenoviruses; epithelial cells; human adenovirus type 26; receptor; αvβ3 integrin

Mesh:

Substances:

Year:  2018        PMID: 30333171      PMCID: PMC6288336          DOI: 10.1128/JVI.01474-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling.

Authors:  Junichi Takagi; Benjamin M Petre; Thomas Walz; Timothy A Springer
Journal:  Cell       Date:  2002-09-06       Impact factor: 41.582

2.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

3.  Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy.

Authors:  Ijad Madisch; Gabi Harste; Heidi Pommer; Albert Heim
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

5.  Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.

Authors:  Hualin Li; Elizabeth G Rhee; Katherine Masek-Hammerman; Jeffrey E Teigler; Peter Abbink; Dan H Barouch
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

6.  Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Authors:  Peter Abbink; Angelique A C Lemckert; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Shirley Smits; Lennart Holterman; Irma Damen; Ronald Vogels; Anna R Thorner; Kara L O'Brien; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 7.  Structure of human adenovirus.

Authors:  Glen R Nemerow; Phoebe L Stewart; Vijay S Reddy
Journal:  Curr Opin Virol       Date:  2012-01-18       Impact factor: 7.090

8.  Single-particle EM reveals plasticity of interactions between the adenovirus penton base and integrin αVβ3.

Authors:  David Veesler; Karolina Cupelli; Markus Burger; Peter Gräber; Thilo Stehle; John E Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

9.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

10.  Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors:  Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

View more
  11 in total

1.  Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26).

Authors:  Jack R Hemsath; A Manuel Liaci; Jeffrey D Rubin; Brian J Parrett; Shao-Chia Lu; Tien V Nguyen; Mallory A Turner; Christopher Y Chen; Karolina Cupelli; Vijay S Reddy; Thilo Stehle; M Kathryn Liszewski; John P Atkinson; Michael A Barry
Journal:  J Virol       Date:  2021-11-17       Impact factor: 6.549

2.  Human Adenovirus Type 26 Induced IL-6 Gene Expression in an αvβ3 Integrin- and NF-κB-Dependent Manner.

Authors:  Davor Nestić; Ksenija Božinović; Isabela Drašković; Alen Kovačević; Jolien van den Bosch; Jelena Knežević; Jerome Custers; Andreja Ambriović-Ristov; Dragomira Majhen
Journal:  Viruses       Date:  2022-03-24       Impact factor: 5.818

Review 3.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

4.  Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor.

Authors:  Alexander T Baker; Rosie M Mundy; James A Davies; Pierre J Rizkallah; Alan L Parker
Journal:  Sci Adv       Date:  2019-09-04       Impact factor: 14.136

Review 5.  Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.

Authors:  Ekramy E Sayedahmed; Ahmed Elkashif; Marwa Alhashimi; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Vaccines (Basel)       Date:  2020-10-01

6.  Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Authors:  Emily A Bates; James A Davies; Jana Váňová; Davor Nestić; Valerie S Meniel; Sarah Koushyar; Tabitha G Cunliffe; Rosie M Mundy; Elise Moses; Hanni K Uusi-Kerttula; Alexander T Baker; David K Cole; Dragomira Majhen; Pierre J Rizkallah; Toby Phesse; John D Chester; Alan L Parker
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 7.200

Review 7.  Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.

Authors:  Lobke C M Hensen; Rob C Hoeben; Selas T F Bots
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

8.  Species D Adenoviruses as Oncolytic Viral Vectors.

Authors:  Brianna L Bullard; Brigette N Corder; Eric A Weaver
Journal:  Viruses       Date:  2020-12-06       Impact factor: 5.818

Review 9.  A Comprehensive View on the Host Factors and Viral Proteins Associated With Porcine Epidemic Diarrhea Virus Infection.

Authors:  Yi Hu; Xiaohong Xie; Lingchen Yang; Aibing Wang
Journal:  Front Microbiol       Date:  2021-12-07       Impact factor: 5.640

10.  To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia.

Authors:  Maha Othman; Alexander T Baker; Elena Gupalo; Abdelrahman Elsebaie; Carly M Bliss; Matthew T Rondina; David Lillicrap; Alan L Parker
Journal:  J Thromb Haemost       Date:  2021-08-23       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.